These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17982304)

  • 1. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
    Davidson MH
    Am Heart Hosp J; 2007; 5(4):210-6. PubMed ID: 17982304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When high is low: raising low levels of high-density lipoprotein cholesterol.
    Toth PP
    Curr Cardiol Rep; 2008 Nov; 10(6):488-96. PubMed ID: 18950560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid.
    Schachter M
    Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating mixed dyslipidemias: why and how.
    Ballantyne CM
    Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
    Chapman MJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
    Knopp RH; Paramsothy P; Atkinson B; Dowdy A
    Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia and cardiovascular risk: the importance of early prevention.
    Miller M
    QJM; 2009 Sep; 102(9):657-67. PubMed ID: 19498039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.